{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:53:12Z","timestamp":1782489192398,"version":"3.54.5"},"reference-count":42,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"unspecified","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to evaluate the cost-effectiveness of latent tuberculosis infection (LTBI) screening strategies using interferon-gamma release assays (IGRAs) among migrants, integrating social vulnerability and access barriers into the modelling framework to support more inclusive public health policy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A Markov state-transition model was constructed from a public healthcare payer perspective over a lifetime horizon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Population<\/jats:title>\n                    <jats:p>A hypothetical cohort of asymptomatic 30-year-old immigrants originating from six high-incidence countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Screening strategies included IGRA-based LTBI testing paired with various preventive treatment regimens: 3-month once-weekly isoniazid plus rifapentine (3HP) under directly observed therapy (DOT), 3HP under self-administered therapy, 1-month daily isoniazid plus rifapentine (1HP) under DOT, 4-month daily self-administered rifampin (4R), 3-month daily self-administered isoniazid plus rifampin, 6-month daily self-administered isoniazid, 9-month daily self-administered isoniazid, pre-entry chest X-ray, postentry chest X-ray, postentry artificial intelligence (AI)-assisted chest X-ray and no screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), TB cases and TB-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among all evaluated strategies, IGRA with 3HP under DOT was the most cost-effective strategy (US$200.1; 25.1042 QALYs; ICER vs 4R: US$29 182 per QALY gained). The current pre-entry chest X-ray remained the least costly option as screening expenses are borne by applicants. Cost-effectiveness was strongly influenced by screening access and the risk of TB reactivation. At a willingness-to-pay threshold of US$50 000 per QALY gained, IGRA with 3HP under DOT, AI-assisted chest X-ray and IGRA with 4R showed probabilities of cost-effectiveness of 40.0%, 27.4% and 22.9%, respectively. For 122\u2009454 immigrants entering Japan in 2023, IGRA with 3HP under DOT was projected to prevent 1403 TB cases and 479 TB-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IGRA with 3HP under DOT provides strong cost-effectiveness and preventive impact. IGRA with 1HP under DOT also shows promising potential, contingent on rifapentine pricing and strengthened public health support. Integrating LTBI screening with improved access to screening and healthier living environments may reduce TB reactivation among migrants and promote more equitable health outcomes, particularly for socially vulnerable groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-112006","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:00:31Z","timestamp":1777910431000},"page":"e112006","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of latent tuberculosis infection screening using interferon-gamma release assays among migrants to Japan: a Markov modelling study incorporating social vulnerability and access barriers"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-4300","authenticated-orcid":false,"given":"Akiko","family":"Kowada","sequence":"first","affiliation":[{"name":"Department of Occupational Health, Kitasato University Graduate School of Medical Sciences, Sagamihara, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026062608311405000_16.5.e112006.1","unstructured":"WHO . Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management. Geneva: World Health Organization, 2018."},{"key":"2026062608311405000_16.5.e112006.2","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.2105\/AJPH.2015.302662","article-title":"Preventing Infectious Pulmonary Tuberculosis Among Foreign-Born Residents of the United States","volume":"105","author":"Davidow","year":"2015","journal-title":"Am J Public Health"},{"key":"2026062608311405000_16.5.e112006.3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5365\/wpsar.2017.8.3.003","article-title":"Pulmonary tuberculosis and non-recent immigrants in Japan - some issues for post-entry interventions","volume":"8","author":"Kawatsu","year":"2017","journal-title":"Western Pac Surveill Response J"},{"key":"2026062608311405000_16.5.e112006.4","unstructured":"Tuberculosis surveillance center, department of epidemiology and clinical research, the research institute of tuberculosis . Statistics of tuberculosis in Japan: annual report 2024. Tokyo Japan Anti-Tuberculosis Association; 2024. Available: https:\/\/jata-ekigaku.jp\/nenpou\/"},{"key":"2026062608311405000_16.5.e112006.5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/aje\/kwab150","article-title":"Modeling the Cost-Effectiveness of Latent Tuberculosis Screening and Treatment Strategies in Recent Migrants to a Low-Incidence Setting","volume":"191","author":"Dale","year":"2022","journal-title":"Am J Epidemiol"},{"key":"2026062608311405000_16.5.e112006.6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3201\/eid2504.171630","article-title":"Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries","volume":"25","author":"Campbell","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2026062608311405000_16.5.e112006.7","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.ijid.2020.03.010","article-title":"Cost-effectiveness of IGRA\/QFT-Plus for TB screening of migrants in Oman","volume":"92S","author":"Al Abri","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2026062608311405000_16.5.e112006.8","unstructured":"Ministry of Justice . Immigration statistics. Tokyo Ministry of Justice; 2021. Available: https:\/\/www.e-stat.go.jp\/dbview?sid=0003288054"},{"key":"2026062608311405000_16.5.e112006.9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-3-200808050-00241"},{"key":"2026062608311405000_16.5.e112006.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"2026062608311405000_16.5.e112006.11","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.3390\/ijerph20126150","article-title":"A Study on the Health-Related Issues and Behavior of Vietnamese Migrants Living in Japan: Developing Risk Communication in the Tuberculosis Response","volume":"20","author":"Lee","year":"2023","journal-title":"IJERPH"},{"key":"2026062608311405000_16.5.e112006.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029988","article-title":"Mental well-being of international migrants to Japan: a systematic review","volume":"9","author":"Miller","year":"2019","journal-title":"BMJ Open"},{"key":"2026062608311405000_16.5.e112006.13","unstructured":"Igakutsushin-sya . National fee schedule and medical insurance reimbursement table in Japan. Tokyo Igakutsushin-sya; 2024."},{"key":"2026062608311405000_16.5.e112006.14","unstructured":"Ministry of Health, Labour and Welfare . Long-term care insurance: home-visit nursing service fee schedule, 2024. Available: https:\/\/www.mhlw.go.jp\/stf\/newpage_16033.html [Accessed 30 Mar 2026]."},{"key":"2026062608311405000_16.5.e112006.15","unstructured":"Organisation for Economic Co-operation and Development . Annual purchasing power parities and exchange rates. Paris OECD; 2025. Available: https:\/\/www.oecd.org\/en\/data\/indicators\/purchasing-power-parities-ppp.html"},{"key":"2026062608311405000_16.5.e112006.16","unstructured":"World Health Organization . Making choices in health: who guide to cost-effectiveness analysis. Geneva World Health Organization; 2003. Available: https:\/\/apps.who.int\/iris\/handle\/10665\/42699"},{"key":"2026062608311405000_16.5.e112006.17","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1200","article-title":"Prevalence of latent tuberculosis infection in Asian nations: A systematic review and meta-analysis","volume":"12","author":"Shrestha","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2026062608311405000_16.5.e112006.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.08.018"},{"key":"2026062608311405000_16.5.e112006.19","doi-asserted-by":"crossref","unstructured":"Kazemzadeh S , Kiraly AP , Nabulsi Z , et al . Prospective Multi-Site Validation of AI to Detect Tuberculosis and Chest X-Ray Abnormalities. NEJM AI 2024;1. doi:10.1056\/AIoa2400018","DOI":"10.1056\/AIoa2400018"},{"key":"2026062608311405000_16.5.e112006.20","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"2026062608311405000_16.5.e112006.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"2026062608311405000_16.5.e112006.22","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.cmi.2024.06.024","article-title":"One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial","volume":"30","author":"Huang","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026062608311405000_16.5.e112006.23","doi-asserted-by":"publisher","DOI":"10.7326\/M17-1150"},{"key":"2026062608311405000_16.5.e112006.24","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.12.0510"},{"key":"2026062608311405000_16.5.e112006.25","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2011.13240","article-title":"Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis","volume":"141","author":"Fresard","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"2026062608311405000_16.5.e112006.26","doi-asserted-by":"publisher","DOI":"10.1086\/427802"},{"key":"2026062608311405000_16.5.e112006.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa031667"},{"key":"2026062608311405000_16.5.e112006.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS One"},{"key":"2026062608311405000_16.5.e112006.29","unstructured":"Ministry of health labour and welfare, Japan . Vital statistics 2021. Tokyo Ministry of Health Labour and Welfare; 2021. Available: https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/vs01.html"},{"key":"2026062608311405000_16.5.e112006.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-05712-1","article-title":"Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: retrospective analysis of Japan tuberculosis surveillance data","volume":"21","author":"Kawatsu","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2026062608311405000_16.5.e112006.31","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-014-0858-6"},{"key":"2026062608311405000_16.5.e112006.32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00355.x"},{"key":"2026062608311405000_16.5.e112006.33","unstructured":"Ministry of Health, Labour and Welfare, Japan . Establishment of reference values for cost-effectiveness evaluation. Tokyo Ministry of Health, Labour and Welfare; 2018. Available: https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-12404000-Hokenkyoku-Iryouka\/0000211609.pdf"},{"key":"2026062608311405000_16.5.e112006.34","unstructured":"Japan Ministry of Justice . Statistics on foreign residents. Tokyo Ministry of Justice; 2023. Available: https:\/\/www.moj.go.jp\/isa\/policies\/statistics\/toukei_ichiran_touroku.html"},{"key":"2026062608311405000_16.5.e112006.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00840-2016"},{"key":"2026062608311405000_16.5.e112006.36","unstructured":"Centers for Disease Control and Prevention . Refugee health overseas guidance, immigrant and refugee health. Atlanta CDC; 2025. Available: https:\/\/www.cdc.gov\/immigrant-refugee-health\/hcp\/domestic-guidance\/tuberculosis.html"},{"key":"2026062608311405000_16.5.e112006.37","unstructured":"NHS England . National latent tuberculosis infection testing and treatment programme. London NHS England; 2025. Available: https:\/\/www.england.nhs.uk\/ourwork\/prevention\/tuberculosis-programme\/national-latent-tuberculosis-infection-testing-and-treatment-programme\/"},{"key":"2026062608311405000_16.5.e112006.38","unstructured":"Oman News . Oman introduces mandatory tb screening for expat visa medicals. 2024. Available: https:\/\/www.thearabianstories.com\/2024\/08\/06\/oman-introduces-mandatory-tb-screening-for-expat-visa-medicals\/"},{"key":"2026062608311405000_16.5.e112006.39","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0423"},{"key":"2026062608311405000_16.5.e112006.40","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tmaid.2016.05.010","article-title":"Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries","volume":"14","author":"Kowada","year":"2016","journal-title":"Travel Med Infect Dis"},{"key":"2026062608311405000_16.5.e112006.41","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-12142-4","article-title":"Targeting screening and treatment for latent tuberculosis infection towards asylum seekers from high-incidence countries - a model-based cost-effectiveness analysis","volume":"21","author":"Marx","year":"2021","journal-title":"BMC Public Health"},{"key":"2026062608311405000_16.5.e112006.42","doi-asserted-by":"crossref","first-page":"102889","DOI":"10.1016\/j.jiph.2025.102889","article-title":"Cost-effectiveness of tuberculosis infection screening and treatment among high-tuberculosis risk immigrants and asylum seekers in The Netherlands: A cohort modelling study","volume":"18","author":"Hontelez","year":"2025","journal-title":"J Infect Public Health"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-112006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:39:24Z","timestamp":1782488364000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-112006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-112006"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-112006","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}